Drug · DIN 02420643
FLUZONE QUADRIVALENT
INFLUENZA VIRUS VACCINE QUADRIVALENT TYPES A AND B (SPLIT VIRION). 0.5 ML SINGLE-DOSE PREFILLED SYRINGE
Authorized, but not sold for a year or more
Authorized, but the company reports it has not been sold in Canada for at least 12 months.
Status Dormant since February 25, 2026; first marketed October 15, 2014.
- Drug Identification Number (DIN)
- 02420643
- Company (DIN owner)
- Sanofi Vaccines Canada Ltd.Toronto, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Influenza, inactivated, split virus or surface antigen J07BB02
- Class
- Human
- Record last updated
- October 8, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| HAEMAGGLUTININ-STRAIN A (H1N1) | 15 MCG | 0.5 ML |
| HAEMAGGLUTININ-STRAIN A (H3N2) | 15 MCG | 0.5 ML |
| HAEMAGGLUTININ-STRAIN B (VICTORIA) | 15 MCG | 0.5 ML |
| HAEMAGGLUTININ-STRAIN B (YAMAGATA) | 15 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 10, 2017: NOC 18953New Drug Submission (NDS) · Transfer of drug identification numbers
- February 6, 2014: NOC 15200New Drug Submission (NDS)
Other DINs named FLUZONE QUADRIVALENT
- DIN 02420635 · Cancelled Pre Market
- DIN 02420651 · Cancelled Pre Market
- DIN 02432730 · Dormant